Mark Wegter - Profile and Investment Details

Investor Profile

Mark Wegter is a Private Equity Firm, Investor, Venture Capital based in The Netherlands with a diverse investment portfolio that includes companies such as FoRx Therapeutics, Cybin, Cardiac Dimensions, AM Pharma, Sapiens Steering Brain Stimulation, Syntaxin, Asoyia, eTheRNA immunotherapies, Vico Therapeutics, DNA Script, Hyperion Therapeutics, VarmX, Hybrigenics, Atlantic Therapeutics, Sequana Medical, Xeltis, Pronota, ImCheck Therapeutics, Prosensa, Orphazyme, Heart Metabolics, ViCentra, Nexstim, XyloCor Therapeutics, Mendor, BMEYE, OneProjects, Cardior Pharmaceuticals, Seahorse Bioscience, Nkarta Therapeutics, Simplify Medical, Luxendo, Binx Health, Affimed, Pasteuria Bioscience, Artios Pharma, Cellerix, GTX medical, IlluminOss Medical, Endotronix, Kreatech Diagnostics, Nouscom, Celladon, Mint Solutions, Neuravi, Rainier Therapeutics, Rotation Medical, Alizé Pharma, Vivasure Medical, Immunic, Kuros Biosciences, Merus, Promethera Biosciences, Neurent Medical, Kiadis Pharma, SNIPR Biome, Harvest Automation, arGEN-X, Curetis, Vivoryon Therapeutics, ActoGeniX, Pharvaris, Cobalt Technologies, Trinity Biosystems, OxThera, Arvelle Therapeutics, Vivendy Therapeutics. Over time, Mark Wegter has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Mark Wegter is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Medical Testing, Investment Management, Life Science, Biotech, Mobile, Medical Device, Manufacturing, Healthcare, Biotechnology, Health Diagnostics, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Mark Wegter, as their portfolio suggests a familiarity and interest in this area.

Understanding Mark Wegter’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.